ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.02
-0.02 (-0.33%)
Jan 30, 2026, 4:00 PM EST - Market closed
ImmuCell Revenue
ImmuCell had revenue of $5.51M in the quarter ending September 30, 2025, a decrease of -8.41%. This brings the company's revenue in the last twelve months to $27.77M, up 16.49% year-over-year. In the year 2024, ImmuCell had annual revenue of $26.49M with 51.64% growth.
Revenue (ttm)
$27.77M
Revenue Growth
+16.49%
P/S Ratio
1.95
Revenue / Employee
$330,587
Employees
84
Market Cap
54.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.49M | 9.02M | 51.64% |
| Dec 31, 2023 | 17.47M | -1.10M | -5.90% |
| Dec 31, 2022 | 18.57M | -675.01K | -3.51% |
| Dec 31, 2021 | 19.24M | 3.90M | 25.43% |
| Dec 31, 2020 | 15.34M | 1.62M | 11.80% |
| Dec 31, 2019 | 13.72M | 2.74M | 24.91% |
| Dec 31, 2018 | 10.99M | 555.21K | 5.32% |
| Dec 31, 2017 | 10.43M | 887.13K | 9.30% |
| Dec 31, 2016 | 9.54M | -684.73K | -6.69% |
| Dec 31, 2015 | 10.23M | 2.63M | 34.64% |
| Dec 31, 2014 | 7.60M | 1.59M | 26.46% |
| Dec 31, 2013 | 6.01M | 617.24K | 11.45% |
| Dec 31, 2012 | 5.39M | 278.79K | 5.45% |
| Dec 31, 2011 | 5.11M | 724.95K | 16.53% |
| Dec 31, 2010 | 4.39M | -119.56K | -2.65% |
| Dec 31, 2009 | 4.51M | -122.55K | -2.65% |
| Dec 31, 2008 | 4.63M | -6.21M | -57.31% |
| Dec 31, 2007 | 10.84M | 1.73M | 19.04% |
| Dec 31, 2006 | 9.11M | -109.26K | -1.19% |
| Dec 31, 2005 | 9.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| TScan Therapeutics | 8.42M |
| Radiopharm Theranostics | 8.20M |
| Lipocine | 4.32M |
| Alterity Therapeutics | 3.57M |
| Nutriband | 2.28M |
| Impact BioMedical | 25.00K |
ICCC News
- 23 days ago - ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 24 days ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 - GlobeNewsWire
- 25 days ago - ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus - GlobeNewsWire
- 5 weeks ago - ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® - GlobeNewsWire
- 2 months ago - ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell Announces Onboarding of New CEO and Related Management Changes - GlobeNewsWire